637-60-5

应用筛选条件

关键词:'637-60-5'

显示 1-2 共 2 条结果关于 "637-60-5" 范围论文

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Stephen H Petersdorf et al.

Blood, 121(24), 4854-4860 (2013-04-18)

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day

Proteomic profile‑based screening of potential protein biomarkers in the urine of patients with nephrotic syndrome.

Yu Wang et al.

Molecular medicine reports, 16(5), 6276-6284 (2017-08-30)

Nephrotic syndrome is not a single disease; rather, it is a term for numerous diseases and pathological types. Renal biopsy is of use in determining the diagnosis and prognosis, and for guiding treatment; however, the use of this intervention is

1/1